INTRODUCTION
Lung cancer remains the leading cause of cancerrelated deaths worldwide, with non-small-cell lung cancer (NSCLC) accounting for approximately 85% of all diagnosed patients. 1 For early-stage NSCLC, including stage I and II and a subset of stage III disease, the standard and potentially curative treatment is radical resection. 2 The seventh edition of the American Joint Committee on Cancer TNM classification represents the most widely used staging system, in which patients with nonmetastatic NSCLC are stratified based on tumor size and invasion, as well as extent of lymph node involvement.
3 However, survival of patients with the same stage varies widely. [4] [5] [6] It is believed that other independent prognostic factors such as sex, age, histology, and treatment-related factors could significantly contribute to individualized prediction of survival. [4] [5] [6] Nomograms have been accepted as reliable tools to quantify risk by incorporating and illustrating important factors for oncologic prognoses.
7-9 By creating an intuitive graph of a statistical predictive model, a nomogram gives rise to a numerical probability of a clinical event, such as overall survival (OS). In several types of cancers, nomograms have been proved to generate more precise prediction when compared with the traditional TNM staging systems.
10,11 However, nomograms for predicting long-term survival outcome after surgery in NSCLC are scarce. In this study, we aimed to build a nomogram for resected NSCLC by combining known clinicopathologic variables based on the data from a multi-institutional registry in China. In addition, we used a separate cohort from the International Association for the Study of Lung Cancer (IASLC) database to externally validate it. ) or complications (including bronchopleural fistula, chylothorax, hemothorax, transfusion, respiratory failure, arrhythmia, myocardial infarct, cardiovascular complications, prolonged air leak of Ͼ 5 days, pneumonia lung embolism, empyema, and wound infection). Standardized clinical data for consecutive patients treated in each of the seven institutions were entered into an independent central database at the Baird Institute for Applied Heart and Lung Surgical Research in Sydney, Australia. Follow-up data for all patients were obtained from their most recent medical review, which consisted of a clinical examination and an assessment of chest x-rays or computed tomography scans. Patients' survival time was calculated from the surgery date to the date of death or last contact. Pathologic staging was characterized according to the seventh edition of the American Joint Committee on Cancer TNM staging system. An independent biostatistician managed and maintained the collected data.
PATIENTS AND METHODS

Patient Population and Data Processing
Only patients diagnosed with NSCLC who underwent radical resection were included in the study. Patients who underwent resection for local advanced or metastatic disease (TNM stage IIIB or stage IV) were excluded. Variables with more than 10% missing values were not eligible for analysis. In addition, patients with any missing value on the eligible variables were excluded from subsequent processing. Continuous variables were transformed into categorical variables based on recognized cutoff values (for age) or median number (for blood loss volume, number of obtained lymph nodes, and lymph node station). 13 To examine the generalizability of the model, an external validation cohort was provided by the IASLC lung cancer database. The cohort is composed of 2,148 patients with stage I to III NSCLC diagnosed between 1999 and 2010 in China, Europe, and North America. It should be noted that patients in this cohort from China were treated at the Guangdong General Hospital and Shanghai Lung Tumor Medical Center and are completely distinct from the patients in the primary multi-institutional registry. Only patients with surgically resected, nonmetastatic disease were included, and all patients were required to have sufficient information to score all variables in the established nomogram. Patients with N3 disease were excluded because they could not be scored according to the nomogram. Although we did not include patients with T4N2 disease when building the nomogram, the statisticians from the IASLC included these patients according to the principle of validation because these patients could be scored by the nomogram. Including these patients tested the validity of the nomogram in a wider set of patients.
Construction of the Nomogram
In the training set, survival curves for different variable values were generated using the Kaplan-Meier estimates and were compared using the log-rank test. Variables that achieved significance at P Ͻ .05 were entered into the multivariable analyses via the Cox regression model. Statistical analyses to identify independent prognostic factors were conducted in SPSS 17.0 for Windows (SPSS, Chicago, IL). On the basis of the results of the multivariable analysis, a nomogram was formulated by R 2.14.1 (http://www.r-project.org) with the survival and rms package. 14 A final model was selected using a backward step-down process, which used the Akaike information criterion as a stopping rule.
15
Validation and Calibration of the Nomogram
The nomogram was subjected to 1,000 bootstrap resamples for internal validation of the primary training cohort and external validation with the IASLC cohort. The model performance for predicting outcome was evaluated by calculating the concordance index (C-index). 16 The value of the C-index ranges from 0.5 to 1.0, with 0.5 indicating a random chance and 1.0 indicating a perfect ability to correctly discriminate the outcome with the model. Comparison of the C-index of two different models was based on methods previously described. 17 Calibration of the nomogram for 1-, 3-, and 5-year OS was performed by comparing the predicted survival with the observed survival after bias correction.
Risk Group Stratification Based on the Nomogram Beyond TNM Staging
In addition to numerically comparing the discrimination ability by C-index, we sought to illustrate the independent discrimination ability of the nomogram beyond standard TNM staging. By grouping the patients evenly into different risk groups within a certain TN category according to the total risk scores (from highest to lowest) in the training cohort, we determined the cutoff values. These values were then applied to the IASLC validation cohort, and the respective Kaplan-Meier survival curves were delineated.
RESULTS
Screening Process and Clinicopathologic Characteristics of Patients
Among the collected variables in the primary database, FEV 1 , FEV 1 %, tumor location (central v peripheral), presence of viscera invasion, and smoking history were not suitable for analysis because of a rate of missing values of greater than 10%. Of the 6,111 patients in the primary database, patients without documented staging information (n ϭ 83) and patients who had stage IIIB or IV disease (n ϭ 255) were excluded. In addition, patients who had missing values on any of the examined variables, including histology (n ϭ 140), tumor location (n ϭ 373), resection type (n ϭ 21), sampled lymph nodes (n ϭ 28), sampled lymph node station (n ϭ 27), blood loss volume (n ϭ 292), presence of comorbidity (n ϭ 266), presence of postoperative complications (n ϭ 280), and survival outcome (n ϭ 4), were excluded. Thus, a total of 5,261 patients were included according to the screening criteria. There were 1,746 events (deaths) over a median follow-up time of 3.1 years (range, 3 days to 10.6 years). The median survival time was 7.3 years (95% CI, 6.7 to 7.8 years). The IASLC cohort consisted of the entire 2,148 patients with stage I to III NSCLC diagnosed between 1999 and 2010, which included 209 patients from China, 683 patients from Europe, and 1,256 patients from North America. There were 762 events (deaths) over a median follow-up time of 2.6 years (range, 0 to 9.1 years). The median survival time was 5.6 years (95% CI, 5.1 to 6.2 years). The clinicopathologic characteristics of patients in the primary and IASLC validation cohorts are listed in Table 1 .
Independent Prognostic Factors in the Training Set
The results of the univariable analysis are listed in Table 2 . Female sex (v male; P Ͻ .001) and younger age (Ͻ 60 v 60 to 70 v Ͼ 70; P Ͻ .001) were associated with better prognosis. Among all cell types, bronchioloalveolar carcinoma subtype had the most favorable survival, followed by squamous cell carcinoma, adenocarcinoma, largecell carcinoma/adenosquamous carcinoma, and others (P Ͻ .001). Pathologic T (P Ͻ .001) and N categories (P Ͻ .001) were also factors that had an impact on survival. With respect to factors associated with surgery, we found that patients who underwent pneumonectomy experienced less favorable survival compared with patients who underwent lobectomy, sleeve resection, or wedge resection (P Ͻ .001). Patients who received and successfully finished a complete VATS resection had superior survival than patients who did not receive or complete a minimally invasive surgery (P Ͻ .001). Interestingly, there was no significant survival difference between Eastern Cooperative Oncology Group performance status of 0 and 1 (P ϭ .486). Some parameters obtained from the perioperative period, including number of lymph nodes obtained (P Ͻ .001) and volume of blood loss (P Ͻ .001), were significant, but other parameters, including the stations of sampled lymph nodes (P ϭ .182), presence of any comorbidity (P ϭ .194), and presence of postoperative complications (P ϭ .081), were not. All significant factors in the univariable analysis were entered into the multivariable analysis based on the Cox regression. Age (P Ͻ .001), sex (P ϭ .002), histology (P Ͻ .001), number of obtained lymph nodes (P Ͻ .001), blood loss volume (P Ͻ .001), T category (P Ͻ .001), and N category (P Ͻ .001) remained independent prognostic factors in the Cox model (Table 2) . 
Prognostic Nomogram for OS
A nomogram that incorporated the significant prognostic factors was established (Fig 1 and Table 3 ). Considering the availability of information on blood loss volume in the IASLC validation set, we excluded blood loss volume in the final nomogram without compromising the discriminative ability of the model. The nomogram illustrated T category and N category as sharing the largest contribution to prognosis, followed by the histologic type and age. Number of obtained lymph nodes and sex showed a moderate impact on the survival. Each subtype within these variable was assigned a score on the point scale. By adding up the total score and locating it on the total point scale, we were easily able to draw a straight line down to determine the estimated probability of survival at each time point.
Calibration and Validation of the Nomogram
The calibration plots presented an excellent agreement in the primary cohort and an acceptable agreement in the IASLC validation cohort between the nomogram prediction and actual observation for 1-, 3-, and 5-year OS (Fig 2) . In the primary cohort, the Harrell's C-index for the established nomogram to predict OS (0.71; 95% CI, 0.70 to 0.72) was significantly higher than that of the TNM staging system (0.68; 95% CI, 0.67 to 0.69; P Ͻ .01). In the IASLC cohort, the C-index was also greater for the nomogram prediction (0.67; 95% CI, 0.65 to 0.69) than for the TNM category prediction (0.64; 95% CI, 0.62 to 0.66), although this difference was not statistically significant (P ϭ .06).
Performance of the Nomogram in Stratifying Risk of Patients
We determined the cutoff values by grouping the patients in the training cohort evenly into five subgroups after sorting by total score (score: 0 to 7, 7.1 to 9.6, 9.7 to 13.3, 13.4 to 16.9, and Ն 17); each group represented a distinct prognosis (Table 3 and Appendix Fig A1, online  only) . After applying the cutoff values to group patients in the IASLC cohort, stratification into different risk subgroups allowed significant distinction between Kaplan-Meier curves for survival outcomes within each TN category (Fig 3) .
DISCUSSION
Because NSCLC is remarkably heterogeneous in regard to survival of individual patients, 18 prediction of survival using the TNM staging system is imprecise. Despite several previously reported prognostic models, 6,19 a nomogram has not been developed for early-stage NSCLC. Thus, we sought to develop a postoperative nomogram to predict long-term survival of operable patients.
The primary cohort was obtained from a multi-institutional registry of seven institutions from China. These institutions are all leading medical centers and represent the standard and advanced technical or medical care in China. The wide geographic distribution of patients and large sample size in this cohort guaranteed its representativeness and generalizability for Chinese patients with NSCLC. Through univariable analysis and subsequent multivariable analysis, we identified age, sex, histology, number of obtained lymph nodes, blood loss volume, T category, and N category as independent prognostic factors. These findings were in high concordance with previous reports on risk factors for NSCLC. [20] [21] [22] [23] Notably, the number of obtained lymph nodes was an important factor that has been established in many cancers, [24] [25] [26] and some similar studies also support the relationship between higher number of examined lymph nodes and better survival.
27,28 One of the possible reasons is that with more extensive sampling of lymph nodes, potential metastasized lymph nodes will be cleared out. Moreover, complete sampling of lymph nodes results in precise staging and, therefore, appropriate adjuvant treatments for patients.
It should be noted that, since 2011, the term bronchioloalveolar carcinoma is no longer used in the current IASLC/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma. 29 We encourage users to assign the current terms of adenocarcinoma in situ and minimally invasive adenocarcinoma to the score of the bronchioloalveolar carcinoma category in this nomogram, which indicates the lowest risk for disease-specific death among all histologic subtypes, whereas other adenocarcinoma subtypes should be assigned according to the adenocarcinoma category. In addition, adjuvant chemotherapy and adjuvant radiotherapy were not selected as candidate factors because adjuvant therapies are recommended only for a proportion of patients who had potentially high risk for disease recurrence, such as patients with residual cancer, lymph node involvement, or more aggressive malignancy. The adjuvant therapies, when introduced into the nomogram, have contradictory impact on targeted and nontargeted populations, causing the wrong score to be assigned to nontargeted patients. In addition, a high proportion of missing data and a time bias would be introduced because adjuvant chemotherapy was not a routine treatment in China until 2006. The blood loss volume was a significant factor in the primary cohort, but it was not recorded in the IASLC database. We cautiously decided not to include this factor in the final nomogram because the C-index improved by only 0.004 after adding it to the current model. In addition, we also tested an altered model by putting age and obtained lymph node count into the nomogram as a continuous variable, but discrimination was slightly impaired (C-index, 0.70).
Validation of the nomogram is essential to avoid overfitting of the model and determine generalizability. 30 In the current study, calibration plots showed optimal agreement between prediction and actual observation, which guaranteed the repeatability and reliability of the established nomogram. More importantly, the model also fit the IASLC cohort, which consisted of patients from China, North America, and Europe; this supported the worldwide use of this nomogram, regardless of race and health care disparities. Discrimination was revealed by the significantly higher C-index of the nomogram compared with the TNM staging system in the training cohort. In the external validation cohort, the discriminative ability was only slightly reduced. In addition, by stratifying patients with disease in the same TNM category into five risk groups using the cutoff values from the training cohort, we separated patients in the IASLC cohort with distinct survival outcomes. Although the magnitudes of discrimination ability of the primary cohort (C-index, 0.71 for nomogram v 0.68 for TNM staging system; 0.03 difference) and external validation cohort (0.67 for nomogram v 0.64 for TNM staging system; 0.03 difference) were similar, significance was not reached (P ϭ .06) and some tangles of survival curves were observed in stage IIB patients. We believe the sample size to be the main contributor to this insignificance. Another reason for this might be that patients with T4N2 disease were included in the validation cohort, whereas such patients were not included when building the nomogram.
To the best of our knowledge, this is the first nomogram for predicting survival of patients with resected NSCLC that is based on a large database with long-term follow-up. Both physicians and patients could perform an individualized survival prediction after surgery through this easy-to-use scoring system. Identifying subgroups of patients at different risk for poor survival might have an impact on the treatment or care option. Selection of patients who need additional therapy or intensive follow-up remains controversial. 31 This scoring system should help physicians to address such issues. In addition, this tool could provide information for patient stratification in the design of clinical study, gaining better equivalence between study arms. We believe that the established nomogram represents a more precise prognostic model compared with the TNM staging system and some previous prognostic models. 4, 6 Still, our nomogram is limited by the retrospective nature of data collection and the failure to incorporate some recognized prognostic parameters (eg, tumor cell differentiation, lymphatic permeation, vascular invasion perineural invasion [32] [33] [34] [35] ), and some important molecular factors (eg, EGFR mutation, ALK-EML4 fusion). Further efforts on prospective data collection and patient follow-up, wider geographic recruitment, and incorporation of some other factors are encouraged to improve this model.
In conclusion, we established and validated a novel nomogram for predicting survival of patients with resected NSCLC. Through this model, clinicians could more precisely estimate the survival of individual patients after surgery and identify subgroups of patients who are in need of a specific treatment strategy. 
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